Read twice and referred to the Committee on Finance.
The bill amends Medicare Part D to reduce patient cost-sharing and utilization-management barriers for certain non-opioid drugs for chronic pain. For plan years beginning January 1, 2026, qualifying non-opioid chronic pain drugs (FDA-labeled for listed chronic pain conditions, non-opioid mechanism, no therapeutically equivalent product sold in the U.S., and with a monthly wholesale acquisition cost at or below a specialty-tier threshold set by the Secretary) would be exempt from the Part D deductible and placed on the lowest cost-sharing tier.
Tradeoff between improved patient access (liberal emphasis) and plan flexibility/cost control (conservative emphasis).
Relative to its intended legislative type, this bill is a clearly focused substantive policy change that is well-specified in statutory amendments and definitions but leaves implementation, fiscal, and enforcement details to existing administrative authorities without additional statutory scaffolding.
The bill amends Medicare Part D to reduce patient cost-sharing and utilization-management barriers for certain non-opioid drugs for chronic pain.
For plan years beginning January 1, 2026, qualifying non-opioid chronic pain drugs (FDA-labeled for listed chronic pain conditions, non-opioid mechanism, no therapeutically equivalent product sold in the U.S., and with a monthly wholesale acquisition cost at or below a specialty-tier threshold set by the Secretary) would be exempt from the Part D deductible and placed on the lowest cost-sharing tier.
The bill also prohibits Medicare prescription drug plans and MA–PD plans from imposing step therapy that requires prior opioid use, and from imposing prior authorization, for those qualifying drugs.
On substance the bill is relatively narrow, administratively straightforward, and framed around expanding access to non‑opioid pain treatments—a goal with potential bipartisan support. However, it imposes binding limits on plan formulary and utilization management tools and likely increases Part D spending, which creates identifiable stakeholder and budgetary friction. Those tradeoffs make passage plausible but not assured without amendment or offset.
Relative to its intended legislative type, this bill is a clearly focused substantive policy change that is well-specified in statutory amendments and definitions but leaves implementation, fiscal, and enforcement details to existing administrative authorities without additional statutory scaffolding.
Tradeoff between improved patient access (liberal emphasis) and plan flexibility/cost control (conservative emphasis).
These are examples from the analysis, not a ranked list of the most-affected groups.
Tradeoff between improved patient access (liberal emphasis) and plan flexibility/cost control (conservative emphasis).
A mainstream liberal would likely view this bill positively as a targeted federal step to expand access to non-opioid pain treatments and reduce reliance on opioids.
They would welcome the removal of deductibles, lowest-tier placement, and bans on prior authorization and opioid-first step therapy as measures that lower financial and administrative barriers for patients.
They may, however, note that the bill does not directly control manufacturer pricing beyond the cost-threshold test and could be concerned about the Secretary’s discretion over that threshold.
A pragmatic centrist would see the bill as a modest, narrowly targeted policy to improve access to non-opioid pain drugs while recognizing tradeoffs.
They would appreciate the aim of reducing barriers to alternatives to opioids but would be cautious about cost implications for Medicare Part D and premium/plan design effects.
They would pay close attention to how the Secretary sets the cost threshold and how the change interacts with plans’ ability to manage formularies and negotiate prices.
A mainstream conservative would likely be skeptical of federal mandates that restrict private plans’ formulary and utilization-management tools.
While sympathetic to improving alternatives to opioids, they would view the bill as an intrusive prescription that could raise costs and reduce insurers’ ability to control spending or steer patients toward cost-effective therapies.
The prohibition on prior authorization and step therapy, plus mandatory lowest-tier placement and deductible waivers, are likely to be seen as limits on market and plan flexibility.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is relatively narrow, administratively straightforward, and framed around expanding access to non‑opioid pain treatments—a goal with potential bipartisan support. However, it imposes binding limits on plan formulary and utilization management tools and likely increases Part D spending, which creates identifiable stakeholder and budgetary friction. Those tradeoffs make passage plausible but not assured without amendment or offset.
The bill has not accumulated any surfaced votes yet.
Tradeoff between improved patient access (liberal emphasis) and plan flexibility/cost control (conservative emphasis).
On substance the bill is relatively narrow, administratively straightforward, and framed around expanding access to non‑opioid pain treatme…
Relative to its intended legislative type, this bill is a clearly focused substantive policy change that is well-specified in statutory amendments and definitions but leaves implementation, fiscal, and enforcement detai…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.